Literature DB >> 16517846

Sensitivities of antigen detection and PCR assays greatly increased compared to that of the standard culture method for screening for group B streptococcus carriage in pregnant women.

Fabien Rallu1, Peter Barriga, Carole Scrivo, Valérie Martel-Laferrière, Céline Laferrière.   

Abstract

Group B streptococcus (GBS) is a major cause of serious infections in neonates. The 2002 revised guidelines of the Centers for Disease Control and Prevention (CDC) for the prevention of perinatal GBS disease recommend that all pregnant women be screened for GBS carriage at between 35 and 37 weeks of gestation and that intrapartum antibiotic prophylaxis be given to carriers. We studied the performances of four different GBS detection assays in the context of antenatal screening. Between May and August 2004, the 605 vaginorectal swab specimens received at our bacteriology laboratory for GBS antenatal detection were tested by the four assays. The standard culture method was done according to the CDC recommendations. The three experimental assays performed with the growth from the selective enrichment (LIM) broth (Todd-Hewitt broth with 15 mug/ml nalidixic acid and 10 mug/ml colistin) after overnight incubation were a GBS antigen detection assay (PathoDx) and two PCR assays (for cfb and scpB). The most accurate assay was the scpB PCR (sensitivity, 99.6%; specificity, 100%), followed by the cfb PCR (sensitivity, 75.3%; specificity, 100%), GBS antigen detection (sensitivity, 57.3%; specificity, 99.5%), and standard culture (sensitivity, 42.3%; specificity, 100%). The GBS antigen detection assay was found to be more sensitive than the standard culture method, and moreover, the assay has a low cost and is easy to perform in all obstetrical centers which have access to the most basic of diagnostic microbiology services. We believe that antigen detection on incubated LIM broth should replace the standard culture method for screening for GBS carriage at 35 to 37 weeks of gestation. The impact of the greater sensitivities of PCR assays on the diminution of neonatal GBS infections remains to be demonstrated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16517846      PMCID: PMC1393163          DOI: 10.1128/JCM.44.3.725-728.2006

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  25 in total

1.  Rapid detection of group B streptococci in pregnant women at delivery.

Authors:  M G Bergeron; D Ke; C Ménard; F J Picard; M Gagnon; M Bernier; M Ouellette; P H Roy; S Marcoux; W D Fraser
Journal:  N Engl J Med       Date:  2000-07-20       Impact factor: 91.245

2.  No increase in rates of early-onset neonatal sepsis by non-group B Streptococcus or ampicillin-resistant organisms.

Authors:  K T Chen; R E Tuomala; A P Cohen; E C Eichenwald; E Lieberman
Journal:  Am J Obstet Gynecol       Date:  2001-10       Impact factor: 8.661

3.  Risks of devices for direct detection of group B streptococcal antigen.

Authors: 
Journal:  J Nurse Midwifery       Date:  1997 Sep-Oct

4.  Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis.

Authors:  S J Schrag; S Zywicki; M M Farley; A L Reingold; L H Harrison; L B Lefkowitz; J L Hadler; R Danila; P R Cieslak; A Schuchat
Journal:  N Engl J Med       Date:  2000-01-06       Impact factor: 91.245

5.  Effect of transport time, temperature, and concentration on the survival of group B streptococci in amies transport medium.

Authors:  K A Stoner; L K Rabe; S L Hillier
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

Review 6.  Perinatal infections due to group B streptococci.

Authors:  Ronald S Gibbs; Stephanie Schrag; Anne Schuchat
Journal:  Obstet Gynecol       Date:  2004-11       Impact factor: 7.661

7.  Specimen storage in transport medium and detection of group B streptococci by culture.

Authors:  Manuel Rosa-Fraile; Enrique Camacho-Muñoz; Javier Rodríguez-Granger; Carmen Liébana-Martos
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

8.  A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates.

Authors:  Stephanie J Schrag; Elizabeth R Zell; Ruth Lynfield; Aaron Roome; Kathryn E Arnold; Allen S Craig; Lee H Harrison; Arthur Reingold; Karen Stefonek; Glenda Smith; Melanie Gamble; Anne Schuchat
Journal:  N Engl J Med       Date:  2002-07-25       Impact factor: 91.245

9.  Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC.

Authors:  Stephanie Schrag; Rachel Gorwitz; Kristi Fultz-Butts; Anne Schuchat
Journal:  MMWR Recomm Rep       Date:  2002-08-16

10.  Comparison of NNA agar culture and selective broth culture for detection of group B streptococcal colonization in women.

Authors:  W M Dunne; C A Holland-Staley
Journal:  J Clin Microbiol       Date:  1998-08       Impact factor: 5.948

View more
  25 in total

1.  Multicenter evaluation of the BD Max GBS assay for detection of group B streptococci in prenatal vaginal and rectal screening swab specimens from pregnant women.

Authors:  Jennifer Riedlinger; Safedin H Beqaj; Marsha A Milish; Stephen Young; Rebecca Smith; Monique Dodd; Rosemary E Hankerd; William D Lebar; Duane W Newton
Journal:  J Clin Microbiol       Date:  2010-09-08       Impact factor: 5.948

2.  Culture-based methods for detection and identification of Streptococcus agalactiae in pregnant women--what are we missing?

Authors:  A Adler; C Block; D Engelstein; D Hochner-Celnikcier; R Drai-Hassid; A E Moses
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11-21       Impact factor: 3.267

3.  Detection of group B streptococci in Lim broth by use of group B streptococcus peptide nucleic acid fluorescent in situ hybridization and selective and nonselective agars.

Authors:  Naomi S Montague; Timothy J Cleary; Octavio V Martinez; Gary W Procop
Journal:  J Clin Microbiol       Date:  2008-07-30       Impact factor: 5.948

4.  Antepartum screening for group B Streptococcus by three FDA-cleared molecular tests and effect of shortened enrichment culture on molecular detection rates.

Authors:  Brianne A Couturier; Trent Weight; Haley Elmer; Robert Schlaberg
Journal:  J Clin Microbiol       Date:  2014-07-09       Impact factor: 5.948

5.  Comparison of the AmpliVue, BD Max System, and illumigene Molecular Assays for Detection of Group B Streptococcus in Antenatal Screening Specimens.

Authors:  Shelley A Miller; Eszter Deak; Romney Humphries
Journal:  J Clin Microbiol       Date:  2015-03-18       Impact factor: 5.948

6.  Group B streptococcus prevalence in pregnant women from North-Eastern Italy: advantages of a screening strategy based on direct plating plus broth enrichment.

Authors:  Marina Busetti; Pierlanfranco D'Agaro; Cesare Campello
Journal:  J Clin Pathol       Date:  2006-12-20       Impact factor: 3.411

7.  Detection of group B Streptococcus bacteria in LIM enrichment broth by peptide nucleic acid fluorescent in situ hybridization (PNA FISH) and rapid cycle PCR.

Authors:  D A Wilson; G S Hall; G W Procop
Journal:  J Clin Microbiol       Date:  2010-03-03       Impact factor: 5.948

8.  Temporal characterization of carrot broth-enhanced real-time PCR as an alternative means for rapid detection of Streptococcus agalactiae from prenatal anorectal and vaginal screenings.

Authors:  Erik Munson; Maureen Napierala; Kimber L Munson; Anne Culver; Jeanne E Hryciuk
Journal:  J Clin Microbiol       Date:  2010-10-27       Impact factor: 5.948

9.  Comparison of carrot broth- and selective Todd-Hewitt broth-enhanced PCR protocols for real-time detection of Streptococcus agalactiae in prenatal vaginal/anorectal specimens.

Authors:  Timothy Block; Erik Munson; Anne Culver; Katharine Vaughan; Jeanne E Hryciuk
Journal:  J Clin Microbiol       Date:  2008-09-17       Impact factor: 5.948

10.  Evaluation of a novel real-time PCR test based on the ssrA gene for the identification of group B streptococci in vaginal swabs.

Authors:  Martina Wernecke; Ciara Mullen; Vimla Sharma; John Morrison; Thomas Barry; Majella Maher; Terry Smith
Journal:  BMC Infect Dis       Date:  2009-09-04       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.